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Recent recommendations by the Food and Drug Administration1 and the European Medicines
Agency2 are to limit the clinical use of linear gadolinium-based contrast agents (GBCAs) due to
convincing evidence of deposition in tissues. Macrocyclic GBCA continued to be considered
safe, provided that patients have normal renal function. To date, given the low sensitivity of
conventional MRI, there has been a debate about the signal increase following the injections of
a macrocyclic GBCA.3,4
To overcome the relative insensitivity of MRI for gadolinium,5,6 inductively coupled plasma
mass spectrometry (ICP-MS) has become a useful tool to measure gadolinium in human
tissues.7,8 When coupled with a laser ablation system (LA), LA-ICP-MS can be used as a mo-
lecular microscope reaching lateral resolution in the micrometer range.9 We used LA-ICP-MS
(Materials and Methods e-1, links.lww.com/NXI/A85) to retrospectively analyze human brain
tissue. Exclusion criteria were reported linear GBCA application, an impaired renal function at
the time point of gadolinium application, contrast enhancement in the cerebellum onMRI, and
structural cerebellar changes (tumor, inflammation, edema, hypoxia, or demyelination). In-
clusion criteria were a diagnostic autopsy with archived paraffin-embedded tissue in the archive
of the Department of Neuropathology Charite´-Universita¨tsmedizin Berlin and recorded ap-
plication of macrocyclic GBCA for diagnostic MRI analysis before death. Autopsy tissue sec-
tions from the cerebellum of 2 patients were chosen randomly. An age-matched control was
a randomly selected patient without recorded GBCA application.
The first patient (Gd1) was a woman, aged 65 years, died because of sepsis with endocarditis.
The cerebral MRI with IV application of 7 mL Gadovist was performed 2 weeks before death
due to cerebral ischemic infarction. The second patient (Gd2) was a man, aged 63 years, died
because of pneumonia and heart failure. He underwent 4 MRI scans with IV administration of
macrocyclic GBCA before death due to anti-NMDA-R encephalitis (13 mL Dotarem 4 weeks,
7 mL Gadovist 9 weeks, 15 mL Dotarem 22 weeks, and 7 mL Gadovist 25 weeks before death).
The control (Co1) was a man, aged 54 years, died because of a traumatic brain injury with no
history of receiving any GBCA.
The possibility of gadolinium accumulation due to environmental exposure could be excluded
by the analysis of another element of the lanthanides family, europium (figure e-1 links.lww.
com/NXI/A83), and an age-matched control with no reported GBCA application (figure).
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As previous MRI studies showed high levels of GBCA-derived
gadolinium depositions in the dentate nucleus,10 we analyzed
the cerebellum. We could detect gadolinium signal in the
dentate nucleus and cerebellar cortex of patient Gd1, who
received macrocyclic GBCAs 2 times including the last ap-
plication 2 weeks before death. The signal colocalized with
iron, copper, zinc, and phosphorous (figure). Accumulation of
gadolinium and phosphorous in this patient in the white
mater could not be explained by an artifact because the
amounts of iron, copper, and sulfur in that area are very low
(figure).
The cerebellar section of the second patient (Gd2), who re-
ceived macrocyclic GBCA 4 times, including the last appli-
cation 4 weeks before death, shows substantially lower
gadolinium signal in the dentate nucleus in comparison to
Gd1 (figure e-2 links.lww.com/NXI/A84). The different
amount of residual gadolinium could be in accordance with
Figure Representative images of the cerebellum of patient Gd1 who received Gadovist 2 weeks before death and the
control patient
Patient Gd1 (A) and control patient (B): (a) Light image of a paraffin-embedded section through the cerebellum. (b–f) LA-ICP-MS element distributionmaps of
phosphorus (P), gadolinium (Gd), iron (Fe), zinc (Zn), and copper (Cu). Although the P signal is less in the Gd1 image compared with the control, the relative
intensities show clearly different concentrations of P among the section. In the control image, the signal is higher because of superior instruments settings but
shows a uniform distribution of P with no “hotspot” as in Gd1.
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time-dependent excretion that remains to be studied in large
patient cohorts. Quantification experiments revealed that the
amount of gadolinium in patients Gd1 and Gd2 are 36 and
2 ng/g brain tissue, respectively. The amount of gadolinium
after linear GBCA administration was reported to be
2,100 ng/g in human dentate nucleus after 2 weeks.7 In
contrast to macrocyclic, dechelation was shown for linear
GBCAs in animal studies, leading to deposits that are probably
not washed out over time.6,11,12 Although we can detect pos-
sibly macrocyclic GBCA in our patients, the technique cannot
provide evidence of a potential gadolinium release from the
macrocyclic GBCA. The main limitations of our study are the
use of heterogenic archived human material making it difficult
to control the timing and quality of GBCA injections and
therefore difficult to evaluate a time dependency.
To date, no signs of adverse health effects and no morpho-
logical changes have been associated with gadolinium in the
brain. Nevertheless, the presence of probably macrocyclic
gadolinium in human (cerebellar) tissue should stimulate
further research also on other anatomical sites. This is par-
ticularly important in the context of repetitive gadolinium
administration in patients with neurologic progressive dis-
eases and an impaired blood brain barrier.
Future studies including patients with different numbers of
macrocyclic GBCA applications and longer time intervals be-
fore death (up to decades) with quantitative data are necessary.
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